|
|
Profile
|
Delegates :
CEO, Tsukasa Sugo, Ph.D. |
|
Incorporated :
February 1 , 2018 |
Paid in Capital :
Million yen |
Employees :
人 |
Address :
Shonan Health Innovation Park 26-1, Muraoka Higashi 2-Chome, Fujisawa, Kanagawa-Ken, Japan KANAGAWA
〒251-0012
|
TEL/FAX :
/ |
URL：
https://jp.genaheadbio.co.jp/ |
Attachment :
|
Mission/Background :
We are a unique venture with highly efficient and precise genome editing technology and proprietary nucleic acid delivery technology. We spun out in April 2018 based on the technology built up at Takeda Pharmaceutical Company Limited. |
|
Technology & Business
|
Our speciality of genome editing service is knock-in technology out of more than 150 projects from major domestic and international pharmaceutical companies to academia to generate pathological model cells for iPS cells by SNP conversion, marker labelling for screening, and other applications. With our background and experience in the pharmaceutical industry, we can provide flexible genome editing plans and services. We have research licenses from ERS Genomics Ltd and BROAD INSTITUTE.
Our proprietary nucleic acid delivery technology can deliver nucleic acids to many cells by linking nucleic acids to antibodies (fragments) that can easily reach cells. Nucleic acids are delivered into cells by conjugating them to antibodies (fragments) against transferrin receptors expressed on cells such as muscle, heart, and white blood cells. This unique technology can deliver nucleic acids to tissues that existing methods cannot. In addition, we have begun drug discovery activities using both technologies.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Genome Editing Service
|
Launched
|
We produce genome-edited cells as requested by our clients under the CRISPR/Cas9 license of ERS Genomics and Broad Institute.
|
Extend the track record to 500 modified cells and acquire contracts outside North America (Europe, etc.).
|
Technology alliance for nucleic acid delivery system 1
|
Launched
|
Alliances and collaborations (joint research, licensing, co-development) on anti-CD71 antibody-nucleic acid conjugates.
|
Confirmation of efficacy in new diseases. Additional delivery organs other than skeletal muscle.
|
Technology alliance for nucleic acid delivery system 2
|
Discovery
|
Collaboration (joint research, licensing, co-development) on new nucleic acid delivery methods.
|
Collaboration with partner companies.
|
|
|
|
|
|
|
|
|
|
Highlights
|
For the latest topics, please visit our website at https://en.genaheadbio.co.jp/
|
|
Alliance strategy
|
We are interested in out-licensing, joint research, and business partnerships related to genome editing and our nucleic acid delivery technology.
|
|
|